Johnson & Johnson digs slightly deeper for Guidant
This article was originally published in Clinica
After more than a week of frenzied speculation, Johnson & Johnson and Guidant have emerged from the negotiating room with a $24bn deal for the former to acquire the latter. As Clinica went to press this week, Guidant agreed to a $76 per share cash and stock bid, just $1 up on the $75 offer that the two companies had been widely reported to be stuck on. The acquisition's fully diluted equity value is $25.4bn, and its net acquisition cost $23.9bn as of December 15.